CA2352205A1 - Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du virus de l'hepatite c ou autres togavirus - Google Patents

Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du virus de l'hepatite c ou autres togavirus Download PDF

Info

Publication number
CA2352205A1
CA2352205A1 CA002352205A CA2352205A CA2352205A1 CA 2352205 A1 CA2352205 A1 CA 2352205A1 CA 002352205 A CA002352205 A CA 002352205A CA 2352205 A CA2352205 A CA 2352205A CA 2352205 A1 CA2352205 A1 CA 2352205A1
Authority
CA
Canada
Prior art keywords
compound
virus
formula
alkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002352205A
Other languages
English (en)
Inventor
Clarence Nathaniel Ahlem
James Martin Frincke
Patrick T. Prendergast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbor Biosciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2352205A1 publication Critical patent/CA2352205A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne l'utilisation de composés 17-cétostéroïdes, ainsi que des dérivés, des métabolites et des précurseurs desdits composés, et des sels pharmaceutiquement acceptables de l'un quelconque de ces composés (ci-après appelés collectivement "composés de l'invention") pour le traitement ou la prévention du virus de l'hépatite C et/ou du virus de l'hépatite G chez des patients nécessitant un tel traitement. L'invention concerne en outre des méthodes de traitement ou de prévention d'infections à togavirus, notamment l'infection à un ou plusieurs alphavirus, flavivirus tels que le virus de la fièvre jaune, le virus de l'hépatite C et le virus de l'hépatite G, les virus de la rubéole, les pestivirus tels que le virus de la diarrhée virale des bovins. L'invention concerne enfin des thérapies combinées qui consistent en l'administration d'un ou plusieurs composés de l'invention, tels que définis plus haut, et l'administration d'un ou plusieurs composés choisis parmi des composés facilitant la concentration de plasma, un facteur d'activation des macrophages, des agents d'oxydation, la ribavirine et l'interféron alpha, et/ou la ventilation à l'oxygène. Les composés de l'invention peuvent être également utilisés pour améliorer ou diminuer un ou plusieurs symptômes associés à l'infection à togavirus.
CA002352205A 1998-11-24 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du virus de l'hepatite c ou autres togavirus Abandoned CA2352205A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10992498P 1998-11-24 1998-11-24
US60/109,924 1998-11-24
US12408799P 1999-03-11 1999-03-11
US60/124,087 1999-03-11
US12605699P 1999-03-23 1999-03-23
US60/126,056 1999-03-23
PCT/US1999/028082 WO2000032177A2 (fr) 1998-11-24 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du virus de l'hepatite c ou autres togavirus

Publications (1)

Publication Number Publication Date
CA2352205A1 true CA2352205A1 (fr) 2000-06-08

Family

ID=27380740

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002352205A Abandoned CA2352205A1 (fr) 1998-11-24 1999-11-24 Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement du virus de l'hepatite c ou autres togavirus

Country Status (14)

Country Link
EP (1) EP1133287A2 (fr)
JP (1) JP2002531397A (fr)
KR (1) KR20010101074A (fr)
CN (1) CN1328463A (fr)
AP (1) AP2001002181A0 (fr)
AU (1) AU775614B2 (fr)
BR (1) BR9915644A (fr)
CA (1) CA2352205A1 (fr)
HK (1) HK1042426A1 (fr)
ID (1) ID29864A (fr)
IL (2) IL142942A0 (fr)
NZ (1) NZ511721A (fr)
OA (1) OA11716A (fr)
WO (1) WO2000032177A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6555523B1 (en) 1999-07-08 2003-04-29 Patrick T. Prendergast Use of cirsiliol and derivatives to treat infections
PT1955700E (pt) 1999-09-30 2011-05-04 Harbor Biosciences Inc Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
CN1665515A (zh) 2002-07-02 2005-09-07 科塞普特治疗公司 治疗与干扰素α治疗相关的精神病的方法
EP2298315A1 (fr) * 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Procédés de traitement thérapeutique
ES2374117T3 (es) * 2007-11-15 2012-02-13 Madaus Gmbh Componente de silibinina para el tratamiento de la hepatitis.
CN102993148B (zh) * 2011-09-13 2015-12-09 复旦大学 槲皮素衍生物或其类似物及其应用
WO2013178782A1 (fr) * 2012-05-30 2013-12-05 Universidad De Zaragoza Inhibiteurs allostériques de la protéase ns3 du virus de l'hépatite c virus
CN108003212A (zh) * 2017-12-24 2018-05-08 扬州工业职业技术学院 一种去氢表雄酮-6-葡萄糖苷衍生物及其作为抗丙型肝炎病毒药物的应用
CN110452280B (zh) * 2019-07-25 2020-11-17 中国人民解放军第二军医大学 一类四环三萜酸衍生物及其制备方法与应用
CA3193390A1 (fr) * 2020-09-22 2022-03-31 Andrey Factor Nebuliseur et agents antiviraux nebulises

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
US5837269A (en) * 1989-09-25 1998-11-17 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
EP0901375A1 (fr) * 1996-04-17 1999-03-17 Patrick Thomas Prendergast Therapie associee reposant sur l'utilisation de la dehydroepiandrosterone (dhea)
WO1998047516A1 (fr) * 1997-04-17 1998-10-29 Prendergast Patrick T Therapie combinee mettant en application des 17-cetosteroides et des inhibiteurs d'interleukine, ou interleukine-10 eventuellement avec des inhibiteurs d'interleukine

Also Published As

Publication number Publication date
IL142942A (en) 2006-08-20
EP1133287A2 (fr) 2001-09-19
OA11716A (en) 2005-01-25
CN1328463A (zh) 2001-12-26
ID29864A (id) 2001-10-18
AU3105200A (en) 2000-06-19
IL142942A0 (en) 2002-04-21
WO2000032177A3 (fr) 2001-03-22
BR9915644A (pt) 2001-08-07
AU775614B2 (en) 2004-08-05
WO2000032177A2 (fr) 2000-06-08
JP2002531397A (ja) 2002-09-24
AP2001002181A0 (en) 2001-05-24
NZ511721A (en) 2004-07-30
HK1042426A1 (zh) 2002-08-16
KR20010101074A (ko) 2001-11-14

Similar Documents

Publication Publication Date Title
US6667299B1 (en) Pharmaceutical compositions and treatment methods
US20030060425A1 (en) Immune modulation method using steroid compounds
EP1223941B1 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines par des steroides
WO2002069977A1 (fr) Traitement de déficiences affectant les globules sanguins
AU2002244247A1 (en) Use of certain steroids for treatment of blood cell deficiencies
AU775614B2 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other togaviruses
RU2295534C2 (ru) Полугидрат 16 альфа-бромо-3 бета-гидрокси-5 альфа-андростан-17-он, способ его получения, фармацевтические композиции, применение соединений
AU2004237812B2 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of African and American trypanosomiasis
EP1422234A2 (fr) Steroides avec activité d'immunomodulation, surtout le hemihydrat du 16.alpha.-bromoepiandrosterone
MXPA01005170A (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis c virus and other togaviruses
WO2000032176A2 (fr) Utilisation de composes 17-cetosteroides et de leurs derives, metabolites et precurseurs pour le traitement de la toxoplasmose ou de la cryptosporidiose
AU2005211675B2 (en) Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
ZA200103845B (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in treatment of toxoplasmosis and in the treatment of cryptosporidiosis.
MXPA01005166A (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of malaria and the treatment of african and american trypanosomiasis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued